News

Cybersecurity cascade funding call for SMEs

Published on | 1 month ago

Programmes Cybersecurity

The National Cybersecurity Coordination Centre (NCC-BE) has opened a call to assist Belgian beneficiaries, such as start-ups, scale-ups, SMEs and/or mid-caps, in the uptake or development of digital innovation

The call topic “Developing infrastructure or digital awareness tools using state-of-the-art technologies providing essential capabilities related to cybersecurity for SMEs” may encompass, but is not limited to, the following features:

  1. creating infrastructures that offer cloud computing services, free data backups and/or a reliable domain name system;
  2. creating multi-factor authentication solutions;
  3. creating IT solutions for cybersecurity awareness based on artificial intelligence, using interactive lessons and/or game-based learning techniques and allowing users to track

More information on this call can be found on the Funding & Tenders Portal and on the website of the NCC-BE.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1746 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.